Reply by Atiq, Omair et al.
Unscheduled Screening Tests Cannot
Be Termed as Surveillance
TO THE EDITOR:
We read with great interest the recent article by
Atiq et al.(1) By assessing benefits and harms from
hepatocellular carcinoma (HCC) surveillance, they
found that over one-fourth of patients with cirrhosis
experienced physical harm due to false-positive or
indeterminate surveillance tests, which were more
often related to ultrasound than alpha-fetoprotein.
They pointed out that high false-positive or indetermi-
nate results of ultrasound may induce unnecessary
computed tomography or magnetic resonance imaging
scans, which would cause some degree of physical
harm, such as radiation exposure. We have the follow-
ing concerns.
It cannot be neglected that a major limitation of this
study was its retrospective nature. All 680 patients
with cirrhosis stratified either to the surveillance or
nonsurveillance groups were determined by researchers
only after review of medical records. As the authors
describe, “ultrasounds with indications including ‘sur-
veillance,’ ‘screening,’ ‘rule out HCC,’ and ‘cirrhosis’
were classified as surveillance exams.” However, the
authors did not explain whether these patients under-
went their regular or scheduled screening tests at every
6-month interval according to the recommendations
from the American Association for the Study of Liver
Diseases and the National Comprehensive Cancer
Network.(2) As a matter of fact, if a rigorous standard
is not set for screening interval (for example, under-
going a screening test once a year or more), these tests
should not be termed as surveillance. This may explain
why the detection rate of early HCC, even in those
patients under “surveillance” was far from satisfactory
in this study. In a word, the bias caused by stratifica-
tion error may in all probability lead to an incorrect
conclusion, and the reliability of this conclusion war-
rants careful interpretation and further validation.
In summary, clarification regarding the aforemen-
tioned omission would greatly solidify the conclusions
made by Atiq et al. in their study.
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REPLY:
We appreciate the letters from Dr. Wang and Dr. Xu,
which raise interesting points that are worthy of further
discussion.
In our recent article,(1) we reported that surveillance
was associated with benefits including early tumor
detection in nearly two thirds of patients who developed
hepatocellular carcinoma (HCC); however, surveillance-
related physical harms, defined as diagnostic evaluation
for false-positive or indeterminate screening results,
were also observed in over one fourth of patients. Wang
et al. contested our definitions for screening benefits as
well as screening harms, contending that early tumor
detection was too narrow a definition for benefits and
receipt of diagnostic evaluation for false-positive results
was too liberal for defining screening harms.
The best measure of surveillance benefits would be
improvement in overall survival, given that this is the
goal of cancer screening programs. However, improve-
ment in overall survival can be difficult to demonstrate
definitively in cohort studies given the possibility of
confounding, lead-time, and length-time bias.(2) Early
tumor detection and receipt of curative treatment are
often used as surrogates(2); however, these are recog-
nized as being imperfect given the additional possibil-
ity of overdiagnosis. Wang et al. suggest expanding the
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definition of screening benefits to include any tumor
detection, given potential improvement in survival
with palliative therapies such as transarterial chemo-
embolization. However, doing so would only amplify
biases of using surrogates of survival and would further
overestimate surveillance benefits. In fact, some would
argue that our definition of early stage using Milan
Criteria is too liberal and that we should instead have
used unifocal lesions less than 2 cm, given that this is
the stage at which microvascular invasion is least likely
and curative therapies are most effective.
Surveillance harms can include physical, psychologi-
cal, and financial harms, although we focused on the
proportion of patients experiencing physical harms.(3)
Wang et al. argue that these tests should not be con-
sidered as harms given the necessity of diagnostic eval-
uation in those with positive screening results to
achieve screening benefits. Our definition of screening
physical harms is based on a well-accepted conceptual
model and taxonomy used to characterize screening
harms for other cancers, including colorectal and breast
cancer.(4) The necessity for diagnostic evaluation
among those with true positive screening results does
not diminish the harms related to false-positive or
indeterminate results. In fact, evaluation of diagnostic
test performance using receiver operator characteristic
curve analysis acknowledges the inherent trade-off
between sensitivity and specificity and the importance
of characterizing both aspects. Our study extends
beyond simply measuring the number of false-positive
surveillance tests, but also measures how often these
results led to follow-up diagnostic evaluation. Whereas
suboptimal specificity has been previously described for
alpha fetoprotein,(5) our study is one of the first to sug-
gest that this may also be an issue for abdominal ultra-
sound. The specificity for ultrasound was lower than
previously reported in efficacy trials for several reasons,
including its operator dependency, suboptimal image
quality in patients with obesity or nonalcoholic steato-
hepatitis, and high proportions of diagnostic evaluation
for patients with indeterminate ultrasound results.(6)
Xu et al. highlight our study’s retrospective nature
and the intermittent use of HCC surveillance. Although
all patients in our study had at least one surveillance
test, less than one third underwent three or more sur-
veillance exams and less than 5% underwent semiannual
surveillance over the 3-year period. However, our study
reflects surveillance utilization in everyday clinical prac-
tice, given that previous studies in the United States
have demonstrated that less than 20% of patients
undergo HCC surveillance and less than 5% undergo
semiannual surveillance.(7,8) Although increased surveil-
lance exposure could magnify observed screening bene-
fits, the proportion of patients experiencing screening
harms would also likely increase proportionally. In our
study, screening harms increased from 11.9% among
those with one surveillance exam to nearly one third of
patients with multiple surveillance exams. Therefore, we
would not anticipate the risk-benefit ratio to substan-
tially change in the setting of increased surveillance
exposure; however, we are currently performing a pro-
spective, multicenter cohort study to confirm these
results under different study settings.
Overall, our study should not be taken as an indict-
ment on HCC surveillance. Instead, our data are
meant to inform how we can better balance surveil-
lance benefits and harms and thereby improve the
overall value of HCC surveillance for our patients in
clinical practice.(9)
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Optimal Timing for Hepatitis C Antiviral Therapy in the
Peritransplant Period?
TO THE EDITOR:
In their recent study, Chhatwal et al. performed a
Markov-based microsimulation comparing pretransplant
versus posttransplant treatment with direct-acting antivi-
ral (DAA) agents in hepatitis C virus (HCV)–infected
patients with decompensated cirrhosis who are awaiting
liver transplantation (LT).(1) The study concluded that
the optimal Model for End-Stage Liver Disease
(MELD) score threshold for pretransplant treatment
ranges between 23 and 27, depending on median wait
time to LT within a United Network for Organ Sharing
(UNOS) region. We think these recommendations
should be reevaluated. Our concerns are as follows.
1. The UNOS regional MELD score thresholds for
pretransplant DAA therapy should be further sub-
divided into ABO blood groups. For instance, the
MELD score thresholds of 23 and 27 in UNOS
regions 3 and 9, respectively, also approximate the
mean MELD score at LT within these regions for
blood type AB.(2) This threshold may result in
“MELD purgatory” among patients with this rare
blood type. Less profound variations in other ABO
blood groups may exist as well and should be
adjusted for in this model.
2. In 2016, UNOS region 5 experienced the highest
regional mean MELD score of 32 at LT, which
is not reflected in wait time to LT.(2) Without
adjusting for regional variation in mean MELD
score at LT and the mortality associated with it,
this model may underestimate the threshold for
pretransplant treatment in UNOS regions with
organ shortage and high mean MELD at LT.
3. Because this was not a cost-effectiveness analysis,
HCV-positive donor grafts should not have been
excluded from this analysis given the excellent
response rates with DAA agents in the posttrans-
plant setting. In addition, the national percentage
of usable HCV-positive donor grafts is reported
to be under 5%, considerably lower than the 8%
estimate used in this analysis.(3)
4. The following clinical outcomes were not assessed
and should also be considered in the timing of
DAA therapy: delisting due to clinical improve-
ment or deterioration, reduction in posttransplant
fibrosing cholestatic recurrent HCV infection, and
reduction in retransplantation rates.
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